| Name | Title | Contact Details |
|---|---|---|
Catherine Lee |
Senior Vice President and General Counsel | Profile |
NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world`s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.
Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.
VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.
Cambria Biosciences is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.